Amplifier presents animal data on ATX-304 combined with semaglutide at ENDO 2025

Cambrian Bio/Pipeline companies

Amplifier Therapeutics presented preclinical data from mouse models of diet-induced obesity testing ATX-304, an oral AMPK and mitochondrial activator, alone and combined with semaglutide, as well as after semaglutide withdrawal. The presentation examined body weight, food intake, and body composition across three conditions.

• ATX-304 is a pan-AMPK activator and mitochondrial activator in development for cardiometabolic diseases.
• Study design tested effects on body weight, food intake, and body composition in diet-induced obesity mice.
• Combination with semaglutide and post-semaglutide withdrawal effects were evaluated to understand potential for metabolic rescue.